Literature DB >> 30381984

Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!

Liesbet M Peeters1, Caspar Ep van Munster2, Bart Van Wijmeersch3, Robin Bruyndonckx4, Ilse Lamers3, Niels Hellings1, Veronica Popescu3, Christoph Thalheim5, Peter Feys1.   

Abstract

Personalized treatment is highly desirable in multiple sclerosis (MS). We believe that multidisciplinary measurements including clinical, functional and patient-reported outcome measures in combination with extensive patient profiling can enhance personalized treatment and rehabilitation strategies. We elaborate on four reasons behind this statement: (1) MS disease activity and progression are complex and multidimensional concepts in nature and thereby defy a one-size-fits-all description, (2) functioning, progression, treatment, and rehabilitation effects are interdependent and should be investigated together, (3) personalized healthcare is based on the dynamics of system biology and on technology that confirms a patient's fundamental biology and (4) inclusion of patient-reported outcome measures can facilitate patient-relevant healthcare. We discuss currently available multidisciplinary MS data initiatives and introduce joint actions to further increase the overall success. With this topical review, we hope to drive the MS community to invest in expanding towards more multidisciplinary and longitudinal data collection.

Entities:  

Keywords:  Individualized medicine; data management; multidisciplinary treatment; multiple sclerosis

Mesh:

Year:  2018        PMID: 30381984     DOI: 10.1177/1352458518807076

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  2 in total

1.  Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.

Authors:  Alise Carlson; Marisa P McGinley
Journal:  Mult Scler       Date:  2022-03-16       Impact factor: 6.312

Review 2.  Standardization and digitization of clinical data in multiple sclerosis.

Authors:  Marcus D'Souza; Athina Papadopoulou; Christophe Girardey; Ludwig Kappos
Journal:  Nat Rev Neurol       Date:  2021-01-15       Impact factor: 42.937

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.